Skip to main content

The Leukemia & Lymphoma Society’s Presence at ASH Showcases Progress to Advance Cures and Care for Blood Cancer Patients

RYE BROOK, N.Y., November 28, 2022 – At the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13), The Leukemia & Lymphoma Society (LLS) will be presenting new research, leading sessions on the latest innovations in blood cancer treatment and equitable access to care, and proudly supporting hundreds of LLS-funded researchers who will share their findings. In addition, there will be 20 presentations from current and former LLS Therapy Acceleration Program® (TAP) partners and more than 20 presentations highlighting clinical data for three TAP-supported FDA approved therapies.
“LLS support has been instrumental in the development of nearly every breakthrough in blood cancer treatment, which drives us to redouble our efforts for what comes next,” said Gwen Nichols, M.D., LLS Chief Medical Officer. “Our relentless commitment – from accelerating cures for our youngest blood cancer patients – to filling an unmet need for newly diagnosed adult patients, is on full display with our presence at ASH.”

Top highlights from LLS-funded research at ASH include advances and insights in understanding and treating blood cancers across LLS convened master clinical trials, COVID-19 research from The LLS National Patient Registry (a project of the Michael J. Garil data collective), and more. Additionally, at the Inaugural LLS Research Awards & Networking Event, we will be recognizing esteemed, long-time members of the LLS scientific community as well as young innovators who will change the face of blood cancer research for decades to come. 


LLS supports the entire spectrum of research – from the lab to the patient – and was among the first to recognize the potential of immunotherapy approaches to fight cancer as evidenced by being one of the earliest funders of CAR-T research. At ASH, LLS will convene a panel of world-renowned researchers to discuss new approaches and modalities representing the future of blood cancer treatment: 

  • Navigating the Frontier of Hematological Malignancy Therapies: Experts from the National Cancer Institute, Dana Farber Cancer Institute, Dan L. Duncan Comprehensive Cancer Center, Fred Hutchinson Cancer Center, and Memorial Sloan Kettering Cancer Center will discuss approaches beyond classic CAR T-cells, bispecific antibodies, and progress in pediatric AML, among other groundbreaking topics.
    • Date/Time: Friday, December 9, 202, 7:00-10:00 AM CT
    • Location: Great Hall A/D (Ernest N. Morial Convention Center)


Six years after its launch, LLS continues to deliver on its promise to “Beat AML” through the groundbreaking Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer. Among the data being presented at ASH are patient-reported quality of life outcomes and how they correlate to disease response on targeted therapies as well as long-term follow up data on an oral medication that shifts AML treatment from a difficult-to-tolerate hospital-based chemotherapy regimen to outpatient treatment:

Title & Poster Number Date/Time Location
#1458: Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial Saturday, December 10, 2022, 5:30 PM-7:30 PM CT Hall D (Ernest N. Morial Convention Center)
#2759: Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial Sunday, December 11, 2022, 6:00 PM-8:00 PM CT Hall D (Ernest N. Morial Convention Center)
#834: A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up Monday, December 12, 2022: 4:00 PM CT R02-R05 (Ernest N. Morial Convention Center)
#4085: A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) Monday, December 12, 2022, 6:00 PM-8:00 PM CT Hall D (Ernest N. Morial Convention Center)


Since February 2021, LLS has been conducting and reporting on research about the impact of COVID-19 on blood cancer patients. The National Patient Registry produced the largest data set on vaccine safety and efficacy across all major blood cancer and treatment types. New research on breakthrough infection rates after vaccination will be presented at ASH. The presentations are: 

Title Date/Time Location
Lessons Learned in Using Social Media for Recruitment to a Large Leukemia & Lymphoma Society National Registry Friday, December 9, 2022, 4:22 PM-4:59 PM CT 283-285 (Ernest N. Morial Convention Center)
#2300 Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry Saturday, December 10, 2022, 5:30 PM-7:30 PM Hall D (Ernest N. Morial Convention Center)
#3591 Feasibility and Preliminary Findings of a Novel, Patient-Centric Registry Model to Address Real-World Care Questions for Patients with Hematologic Malignancies Sunday, December 11, 2022, 6:00 PM-8:00 PM CT Hall D (Ernest N. Morial Convention Center)


LLS is committed to ensuring all blood cancer patients have access to clinical trials and the same high-quality treatments. Join us as we discuss ways in which we will drive this vision forward at the following panels: 

Title Topic Time/Date Location
Elevating Equity in Caring for Patients with Hematologic Malignancies In collaboration with Medscape Oncology, this live symposium will increase awareness of health disparities for clinicians treating patients with hematologic malignancies from diverse backgrounds and provide strategies for overcoming barriers to equitable care. Friday, December 9, 2022, 11:30 AM -1:00 PM CT Hyatt Regency New Orleans, Celestin EFGH – Level 3
BMS Global Hematology Patient Advocacy Forum: Health Equity Louis J. DeGennaro, PhD, LLS, President & CEO, will be engaging in a conversation around health equity and best practices for hematology patients and caregivers with BMS’ Patient Advocacy Team and other leaders in this space. Friday, December 9, 2022, 2:00-5:30 PM CT New Orleans Marriott Warehouse Arts Hotel


Leveraging our expertise in convening master clinical trials, LLS developed the Pediatric Acute Leukemia (PedAL) Master Clinical Trial to expedite the development of new targeted treatments for hard-to-treat childhood leukemias and replace one-size-fits-all chemotherapy with therapies tailored to each child’s unique tumor biology. An overview of the study design from the first sub-trial under PedAL will be featured at ASH: 

Title Date/Time Location
#1459 ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine /Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia December 10, 2022, 5:30 PM-7:30 PM CT Hall D (Ernest N. Morial Convention Center)

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information, visit Follow us on Facebook, Twitter, and Instagram.

LLS is one of Fast Company's "2022 Brands That Matter." As the only cancer organization on the list, LLS stands out among brands around the world for its relevancy, cultural impact, ingenuity, and mission impact.

Irene Tung
The Leukemia & Lymphoma Society